RLMD News and Press, Relmada Therapeutics Inc. From 11/11/21

Relmada Therapeutics (NASDAQ:RLMD): Q3 GAAP EPS of -$2.44 misses by $0.84. Press Release As of September 30, 2021, the Company had cash and short-term investments of $88.1 million, compared to cash, cash equivalents, and short-term investments of approximately $117.1 million at December 31, 2...

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results PR Newswire CORAL GABLES, Fla. , Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases o...

Relmada Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire CORAL GABLES, Fla. , Nov. 9, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervo...

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 PR Newswire CORAL GABLES, Fla. , Nov. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology ...

Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress PR Newswire CORAL GABLES, Fla. , Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the...

Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder Relmada is actively enrolling patients in RELIANCE III, a Monotherapy Registrational Phase 3 Study FDA Confirms Rel...

Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit PR Newswire CORAL GABLES, Fla. , Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases ...

Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of...

Relmada Therapeutics, Inc. (RLMD) Q2 2021 Earnings Conference Call August 10, 2021, 16:30 ET Company Participants Timothy McCarthy - LifeSci Advisors Sergio Traversa - CEO & Director Charles Ence - Chief Accounting & Compliance Officer Charles Gorodetzky - Former Scientific Director, ...

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results PR Newswire NEW YORK , Aug. 10, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ...